| Ytd | 28.94% | |
| 1y | 73.97% |
| Open | 57.20 | Prev Close | 57.80 | Low | 56.10 | High | 57.62 | Mkt Cap | 6.92B |
| Vol | 987.16K | Avg Vol | 1.32M | EPS | -3.31 | P/E | N/A | Forward P/E | -24.39 |
| Beta | 0.67 | Short Ratio | 18.07 | Inst. Own | 117.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 52.91 | 200-d Avg | 47.15 | 1yr Est | 60.75 |
SRRK News
BlackRock Inc. acquired a new position in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK)
FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facilityCompany is prep
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d
Scholar Rock NASDAQ: SRRK CEO David Hallal said the company is preparing for a September 30 FDA deci
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that t
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and
Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping th
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperfor
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK)
Scholar Rock said on Friday it would remove Catalent's Indiana manufacturing facility from its appli
Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raise
Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part o
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d
Scholar Rock NASDAQ: SRRK said its resubmitted biologics license application for apitegromab remains
Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of
Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.84) per share which beat the ana
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm PR Newswire NEW YORK
NEW YORK, July 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperfor
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i
Scholar Rock said on Monday a European Union opinion on its experimental spinal muscular atrophy tre
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that t
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report s
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company d
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that t
Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK)
Canaccord Genuity analyst Gary Nachman initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) w
Top Wall Street analysts changed their outlook on top names. For a complete view of all rating chang
Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
Apitegromab BLA resubmission includes Catalent Indiana LLC (part of Novo Nordisk) and second U.S.-ba
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and
Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raise
BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform a
Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:SRRK) with
Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK)
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK)
Citigroup analyst Geoff Meacham initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a B
UBS analyst Michael Yee initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Buy ratin
Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and